LENZ
vs
S&P 500
LENZ
S&P 500
Over the past 12 months, LENZ has underperformed S&P 500, delivering a return of -42% compared to the S&P 500's +14% growth.
Stocks Performance
LENZ vs S&P 500
Performance Gap
LENZ vs S&P 500
Performance By Year
LENZ vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Graphite Bio Inc
Glance View
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).